Record sales of a new hepatitis C drug pushed the first-quarter earnings of Gilead Sciences beyond expectations. The "Squawk on the Street" news team break down its quarterly beat.
1 / 23
CNBC Videos
Wed, Apr 23, 2014 9:43 AM EDT